Who
Darlene M. Deptula-Hicks
Director
Company insider
Files Form 4 as: Director, Aldeyra Therapeutics; Treasurer and CFO, F-star Therapeutics; SVP & Chief Financial Officer, T2 Biosystems; Director, Xenetic Biosciences; SVP, Chief Financial Officer, Palvella Therapeutics; Exec VP of Finance, CFO, Icad.
In numbers
- Trades disclosed
- 43
- Buys
- 2
- Sells
- 3
- Bought
- $23K
- Sold
- $35K
- Companies
- 6
- Companies where not an officer
- 2
- First trade
- 18 Jul 2007
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,557 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,756 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,557 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | ALDX Aldeyra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,756 at $0.00 | filing |
| 8 Mar 2023filed 9 Mar 2023 | F-star Therapeuticsoption or derivative | SEC FORM 4 Code D | —28,426 | filing |
| 8 Mar 2023filed 9 Mar 2023 | F-star Therapeuticsoption or derivative | SEC FORM 4 Code D | —25,894 | filing |
| 8 Mar 2023filed 9 Mar 2023 | F-star Therapeuticsoption or derivative | SEC FORM 4 Code D | —59,823 | filing |
| 8 Mar 2023filed 9 Mar 2023 | F-star Therapeuticsoption or derivative | SEC FORM 4 Code D | —24,902 | filing |
| 8 Mar 2023filed 9 Mar 2023 | F-star Therapeutics | SEC FORM 4 Code U | $220K30,898 at $7.12 | filing |
| 8 Mar 2023filed 9 Mar 2023 | F-star Therapeutics | SEC FORM 4 Code D | $182K25,539 at $7.12 | filing |
| 31 Mar 2022filed 4 Apr 2022 | F-star Therapeuticsoption or derivative | SEC FORM 4 Code A | —24,902 at $0.00 | filing |
| 9 Jan 2022filed 11 Jan 2022 | F-star Therapeuticsoption or derivative | SEC FORM 4 Code A | —59,823 at $0.00 | filing |
| 9 Mar 2021filed 11 Mar 2021 | F-star Therapeuticsoption or derivative | SEC FORM 4 Code A | —25,894 at $0.00 | filing |
| 1 Feb 2021filed 2 Feb 2021 | F-star Therapeutics | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 20 Nov 2020filed 24 Aug 2021 | F-star Therapeutics | SEC FORM 4 Code A | —26,437 at $0.00 | filing |
| 20 Nov 2020filed 24 Nov 2020 | F-star Therapeuticsoption or derivative | SEC FORM 4 Code A | —28,426 at $0.00 | filing |
| 20 Nov 2020filed 24 Nov 2020 | F-star Therapeuticsoption or derivative | SEC FORM 4 Code A | —26,437 at $0.00 | filing |
| 6 Jun 2017filed 8 Jun 2017 | T2 Biosystems | SEC FORM 4 Bought | $14K4,000 at $3.58 | filing |
| 20 Dec 2016filed 15 Jun 2017 | XBIO Xenetic Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 20 Dec 2016filed 15 Jun 2017 | XBIO Xenetic Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
News
Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) Director Sells $1,758,290.88 in StockPVLA · tickerreport.com · 17 Oct 2026Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual ConferencePVLA · manilatimes.net · 15 Oct 2026Palvella Therapeutics (NASDAQ:PVLA) Director Sells $935,202.64 in StockPVLA · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Darlene M. Deptula-Hicks; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.